MapLight Therapeutics, Inc.
NASDAQMPLT heads into today's earnings release with the most bullish analyst consensus it has carried since going public. The analyst setup is unusually clean for a clinical-stage biotech. Every firm covering the stock carries a Buy rating, and price targets have been moving up, not down. Needham raised its target to $42 just today, the day of the print, from $37. UBS initiated in late…
Snapshot as of 19 Jul 2026
MPLT heads into today's earnings release with the most bullish analyst consensus it has carried since going public. The analyst setup is unusually clean for a clinical-stage biotech. Every firm covering the stock…
MapLight Therapeutics heads into its June 4 earnings report with a wave of fresh analyst conviction — and a stock that has moved sharply in the wrong direction. The analyst story is unusually clean for a clinical-stage…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MPLT — free to start on ORTEX.
Sign up for free →Open MPLT on ORTEX